The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models.
BACKGROUND
A decrease in the prevalence of hepatitis C virus antibody (anti-HCV) has been reported among voluntary blood donors in some regions of China. However, the prevalence of HCV among volunteer blood donors in other regions of China has not been reported. The aim of this study was to investigate the seroprevalence of HCV among 559,890 first-time volunteer blood donors recruited during 2004 through 2007 at the Guangzhou Blood Center, China.


METHODS
Anti-HCV was detected using two different third-generation enzyme immunoassay kits. HCV RNA was detected using reverse transcription-polymerase chain reaction (RT-PCR) targeting the 5'-untranslated region of HCV.


RESULTS
Among 559,890 donors, 1877 (0.335%) were positive for anti-HCV. The anti-HCV+ rate was significantly higher in males than females (0.37% vs. 0.28%; p < 0.001) and significantly lower among donors living in Guangdong Province than donors who had migrated from other locations (0.30% vs. 0.40%; p < 0.001). Among the 1877 anti-HCV+ donors, 450 were randomly selected for HCV nucleic acid amplification by RT-PCR. Of these, 270 (60%) were HCV RNA+ and 180 (40%) were HCV RNA-.


CONCLUSIONS
Many donors from outside Guangdong Province were migrant laborers from other areas in China, suggesting that there is regional heterogenicity in HCV prevalence within China. The overall anti-HCV+ rate reported here is among the lowest reported among blood donors in China reflecting the effect of the current recruitment of exclusively volunteer donors.
Fu
Yongshui
Y
Guangzhou Blood Center and the Laboratory of Integrated Biosciences, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xia
Wenjie
W
Wang
Yizhong
Y
Tian
Linwei
L
Pybus
Oliver G
OG
Lu
Ling
L
Nelson
Kenrad
K
D000328:Adult; D001782:Blood Donors; D002681:China; D005260:Female; D006526:Hepatitis C / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D012367:RNA, Viral / Q000097:blood; D016036:Seroepidemiologic Studies
D018937:Hepatitis C Antibodies; D012367:RNA, Viral
J Infect Dis. 2007 Nov 15;196(10):1474-82
18008226
N Engl J Med. 1994 Mar 17;330(11):784-6
8107747
JAMA. 2000 Jul 12;284(2):229-35
10889598
Ann Intern Med. 1995 Sep 1;123(5):330-7
7542854
Transfusion. 1999 Aug;39(8):913
10504132
J Gen Virol. 2006 Jan;87(Pt 1):83-91
16361420
Hepatology. 2000 Mar;31(3):756-62
10706569
J Viral Hepat. 2006 Jan;13(1):34-41
16364080
Science. 2002 Jun 28;296(5577):2339-40
12089428
Rev Med Virol. 2003 Jan-Feb;13(1):57-68
12516062
Nat Med. 2000 May;6(5):578-82
10802716
Clin Infect Dis. 2006 Nov 1;43(9):1154-9
17029134
Hepatology. 2001 Feb;33(2):455-63
11172349
Lancet. 2002 Nov 30;360(9347):1770-5
12480443
J Med Virol. 1997 Mar;51(3):167-74
9139079
Jpn J Infect Dis. 2003 Feb;56(1):19-22
12711821
J Hepatol. 1994 Oct;21(4):634-40
7529274
Transfusion. 2007 Nov;47(11):2011-6
17958529
Wkly Epidemiol Rec. 1999 Dec 10;74(49):425-7
10645164
Transfus Med. 2007 Jun;17(3):210-1
17561867
MMWR Recomm Rep. 2003 Feb 7;52(RR-3):1-13, 15; quiz CE1-4
12585742
Hepatology. 2002 Nov;36(5 Suppl 1):S21-9
12407573
Gastroenterology. 2003 Jul;125(1):80-8
12851873
J Infect Dis. 2008 Nov 1;198(9):1337-44
18767985
Transfusion. 2007 Mar;47(3):529-39
17319836
Clin Infect Dis. 2005 Apr 1;40(7):951-8
15824985
Transfusion. 2008 May;48(5):902-9
18208409
J Hepatol. 2006 Oct;45(4):607-16
16901579
Pathol Biol (Paris). 1993 Feb;41(2):149-53
8327265
Transfusion. 2005 Nov;45(11):1816-22
16271110
Ann Intern Med. 2006 May 16;144(10):705-14
16702586
Lancet. 2001 Jan 6;357(9249):49
11197369
Lancet. 1995 Jul 1;346(8966):61-2
7603178